Does the media prefer MANE or JAZZ?

In the previous week, Jazz Pharmaceuticals had 2 more articles in the media than Veradermics. MarketBeat recorded 5 mentions for Jazz Pharmaceuticals and 3 mentions for Veradermics. Jazz Pharmaceuticals' average media sentiment score of 0.48 beat Veradermics' score of 0.45 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jazz Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MANE or NBIX?

In the previous week, Neurocrine Biosciences had 6 more articles in the media than Veradermics. MarketBeat recorded 9 mentions for Neurocrine Biosciences and 3 mentions for Veradermics. Neurocrine Biosciences' average media sentiment score of 0.72 beat Veradermics' score of 0.45 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neurocrine Biosciences 4 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MANE or CORT?

In the previous week, Corcept Therapeutics had 26 more articles in the media than Veradermics. MarketBeat recorded 29 mentions for Corcept Therapeutics and 3 mentions for Veradermics. Corcept Therapeutics' average media sentiment score of 0.50 beat Veradermics' score of 0.45 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corcept Therapeutics 6 Very Positive mention(s) 6 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to MANE or ELAN?

In the previous week, Elanco Animal Health had 5 more articles in the media than Veradermics. MarketBeat recorded 8 mentions for Elanco Animal Health and 3 mentions for Veradermics. Elanco Animal Health's average media sentiment score of 0.53 beat Veradermics' score of 0.45 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Elanco Animal Health 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AXSM or MANE?

In the previous week, Axsome Therapeutics had 11 more articles in the media than Veradermics. MarketBeat recorded 14 mentions for Axsome Therapeutics and 3 mentions for Veradermics. Axsome Therapeutics' average media sentiment score of 0.77 beat Veradermics' score of 0.45 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 5 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Veradermics (MANE) Competitors

$115.73 -2.41 (-2.04%)

Closing price 03:59 PM Eastern

Extended Trading

$116.00 +0.27 (+0.23%)

As of 07:47 PM Eastern

Compare

MANE vs. JAZZ, NBIX, CORT, ELAN, and AXSM

Should you buy Veradermics stock or one of its competitors? Veradermics's main competitors and comparable companies include Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (NBIX), Corcept Therapeutics (CORT), Elanco Animal Health (ELAN), and Axsome Therapeutics (AXSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Veradermics compare to Jazz Pharmaceuticals?

Veradermics (NYSE:MANE) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Veradermics' net margin of 0.00%. Jazz Pharmaceuticals' return on equity of 33.97% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Jazz Pharmaceuticals	20.45%	33.97%	13.02%

Veradermics has higher earnings, but lower revenue than Jazz Pharmaceuticals. Veradermics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.90	N/A
Jazz Pharmaceuticals	$4.27B	3.57	-$356.15M	$14.50	16.20

In the previous week, Jazz Pharmaceuticals had 2 more articles in the media than Veradermics. MarketBeat recorded 5 mentions for Jazz Pharmaceuticals and 3 mentions for Veradermics. Jazz Pharmaceuticals' average media sentiment score of 0.48 beat Veradermics' score of 0.45 indicating that Jazz Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jazz Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veradermics presently has a consensus target price of $153.00, suggesting a potential upside of 32.20%. Jazz Pharmaceuticals has a consensus target price of $286.72, suggesting a potential upside of 22.07%. Given Veradermics' higher possible upside, research analysts clearly believe Veradermics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Jazz Pharmaceuticals beats Veradermics on 13 of the 15 factors compared between the two stocks.

How does Veradermics compare to Neurocrine Biosciences?

Veradermics (NYSE:MANE) and Neurocrine Biosciences (NASDAQ:NBIX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

92.6% of Neurocrine Biosciences shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Neurocrine Biosciences has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.90	N/A
Neurocrine Biosciences	$2.86B	4.96	$478.60M	$6.82	20.45

In the previous week, Neurocrine Biosciences had 6 more articles in the media than Veradermics. MarketBeat recorded 9 mentions for Neurocrine Biosciences and 3 mentions for Veradermics. Neurocrine Biosciences' average media sentiment score of 0.72 beat Veradermics' score of 0.45 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neurocrine Biosciences	4 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurocrine Biosciences has a net margin of 20.91% compared to Veradermics' net margin of 0.00%. Neurocrine Biosciences' return on equity of 22.43% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Neurocrine Biosciences	20.91%	22.43%	15.64%

Veradermics currently has a consensus target price of $153.00, indicating a potential upside of 32.20%. Neurocrine Biosciences has a consensus target price of $201.09, indicating a potential upside of 44.16%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Neurocrine Biosciences is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Neurocrine Biosciences beats Veradermics on 15 of the 15 factors compared between the two stocks.

How does Veradermics compare to Corcept Therapeutics?

Veradermics (NYSE:MANE) and Corcept Therapeutics (NASDAQ:CORT) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Veradermics presently has a consensus price target of $153.00, suggesting a potential upside of 32.20%. Corcept Therapeutics has a consensus price target of $138.17, suggesting a potential upside of 22.34%. Given Veradermics' stronger consensus rating and higher possible upside, analysts clearly believe Veradermics is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

93.6% of Corcept Therapeutics shares are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Corcept Therapeutics had 26 more articles in the media than Veradermics. MarketBeat recorded 29 mentions for Corcept Therapeutics and 3 mentions for Veradermics. Corcept Therapeutics' average media sentiment score of 0.50 beat Veradermics' score of 0.45 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corcept Therapeutics	6 Very Positive mention(s)	6 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Corcept Therapeutics has a net margin of 6.52% compared to Veradermics' net margin of 0.00%. Corcept Therapeutics' return on equity of 8.26% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Corcept Therapeutics	6.52%	8.26%	6.45%

Corcept Therapeutics has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.90	N/A
Corcept Therapeutics	$761.41M	16.03	$99.65M	$0.42	268.90

Summary

Corcept Therapeutics beats Veradermics on 11 of the 14 factors compared between the two stocks.

How does Veradermics compare to Elanco Animal Health?

Veradermics (NYSE:MANE) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

97.5% of Elanco Animal Health shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Elanco Animal Health had 5 more articles in the media than Veradermics. MarketBeat recorded 8 mentions for Elanco Animal Health and 3 mentions for Veradermics. Elanco Animal Health's average media sentiment score of 0.53 beat Veradermics' score of 0.45 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elanco Animal Health	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Veradermics currently has a consensus target price of $153.00, indicating a potential upside of 32.20%. Elanco Animal Health has a consensus target price of $29.09, indicating a potential upside of 28.64%. Given Veradermics' higher probable upside, equities research analysts plainly believe Veradermics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Veradermics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Elanco Animal Health	-3.96%	8.13%	3.99%

Veradermics has higher earnings, but lower revenue than Elanco Animal Health. Veradermics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.90	N/A
Elanco Animal Health	$4.72B	2.40	-$232M	-$0.41	N/A

Summary

Elanco Animal Health beats Veradermics on 12 of the 15 factors compared between the two stocks.

How does Veradermics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Veradermics has lower revenue, but higher earnings than Axsome Therapeutics. Veradermics is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$776.57M	13.05	-$183.17M	-$3.75	N/A
Veradermics	N/A	N/A	-$70M	-$1.90	N/A

81.5% of Axsome Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Axsome Therapeutics had 11 more articles in the media than Veradermics. MarketBeat recorded 14 mentions for Axsome Therapeutics and 3 mentions for Veradermics. Axsome Therapeutics' average media sentiment score of 0.77 beat Veradermics' score of 0.45 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	5 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veradermics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -24.68%. Veradermics' return on equity of 0.00% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Veradermics	N/A	N/A	N/A

Axsome Therapeutics presently has a consensus target price of $271.85, indicating a potential upside of 40.53%. Veradermics has a consensus target price of $153.00, indicating a potential upside of 32.20%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Axsome Therapeutics is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.86
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Axsome Therapeutics beats Veradermics on 10 of the 15 factors compared between the two stocks.

Get Veradermics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MANE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MANE vs. The Competition

Export

Metric	Veradermics	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$4.84B	$12.42B	$7.21B	$22.88B
Dividend Yield	N/A	2.63%	2.53%	3.62%
P/E Ratio	-60.91	794.80	274.58	28.11
Price / Sales	N/A	830.70	648.78	20.84
Price / Cash	N/A	86.22	76.31	39.12
Price / Book	N/A	10.62	10.44	4.66
Net Income	-$70M	$2.81B	$3.49B	$1.07B
7 Day Performance	13.14%	0.73%	0.51%	-0.67%
1 Month Performance	12.00%	-1.67%	-3.38%	-4.61%
1 Year Performance	N/A	3.07%	16.04%	7.19%

Veradermics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
MANE Veradermics	2.6369 of 5 stars	$115.73 -2.0%	$153.00 +32.2%	N/A	$4.84B	N/A	N/A	21
JAZZ Jazz Pharmaceuticals	4.2419 of 5 stars	$244.60 +0.4%	$286.72 +17.2%	+84.8%	$15.88B	$4.27B	16.87	2,890
NBIX Neurocrine Biosciences	4.7923 of 5 stars	$151.38 +1.3%	$201.09 +32.8%	-3.0%	$15.39B	$2.86B	22.19	2,000
CORT Corcept Therapeutics	3.8679 of 5 stars	$111.28 -0.5%	$138.17 +24.2%	+46.9%	$12.04B	$761.41M	265.13	730
ELAN Elanco Animal Health	4.1687 of 5 stars	$23.08 +0.9%	$29.09 +26.1%	+20.1%	$11.54B	$4.72B	N/A	9,400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:MANE) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veradermics (MANE) Competitors

MANE vs. JAZZ, NBIX, CORT, ELAN, and AXSM

How does Veradermics compare to Jazz Pharmaceuticals?

Summary

How does Veradermics compare to Neurocrine Biosciences?

Summary

How does Veradermics compare to Corcept Therapeutics?

Summary

How does Veradermics compare to Elanco Animal Health?

Summary

How does Veradermics compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MANE vs. The Competition

Veradermics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veradermics (MANE) Competitors

MANE vs. JAZZ, NBIX, CORT, ELAN, and AXSM

How does Veradermics compare to Jazz Pharmaceuticals?

Do insiders & institutionals have more ownership in MANE or JAZZ?

Is MANE or JAZZ more profitable?

Which has preferable earnings and valuation, MANE or JAZZ?

Does the media prefer MANE or JAZZ?

Do analysts rate MANE or JAZZ?

Summary

How does Veradermics compare to Neurocrine Biosciences?

Do institutionals & insiders hold more shares of MANE or NBIX?

Which has preferable earnings & valuation, MANE or NBIX?

Does the media favor MANE or NBIX?

Is MANE or NBIX more profitable?

Do analysts prefer MANE or NBIX?

Summary

How does Veradermics compare to Corcept Therapeutics?

Do analysts prefer MANE or CORT?

Do institutionals & insiders hold more shares of MANE or CORT?

Does the media prefer MANE or CORT?

Is MANE or CORT more profitable?

Which has stronger valuation & earnings, MANE or CORT?

Summary

How does Veradermics compare to Elanco Animal Health?

Do insiders and institutionals have more ownership in MANE or ELAN?

Does the media refer more to MANE or ELAN?

Do analysts rate MANE or ELAN?

Is MANE or ELAN more profitable?

Which has stronger earnings and valuation, MANE or ELAN?

Summary

How does Veradermics compare to Axsome Therapeutics?

Which has stronger valuation & earnings, AXSM or MANE?

Do insiders & institutionals believe in AXSM or MANE?

Does the media prefer AXSM or MANE?

Is AXSM or MANE more profitable?

Do analysts prefer AXSM or MANE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MANE vs. The Competition

Veradermics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools